#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA977277	B	Inhibition of SHP2 using 6,8-difluoro-4-methylumbelliferyl phosphate as substrate		1	ALA1139429	single protein format	Scientific Literature
2.	ALA2067245	B	Binding affinity to human synthetic proadrenomedullin N-terminal 20 peptide assessed as reduction in absorbance at 1 uM after 1 hr by monoclonal antibody method	Homo sapiens	32	ALA2062468	single protein format	Scientific Literature
3.	ALA2067246	B	Binding affinity to human proadrenomedullin N-terminal 20 peptide at 500 uM by NMR spectroscopy	Homo sapiens	2	ALA2062468	single protein format	Scientific Literature
4.	ALA2067247	B	Binding affinity to human proadrenomedullin N-terminal 20 peptide assessed as fragmentation of PAMP protein at 500 uM by MS analysis	Homo sapiens	1	ALA2062468	single protein format	Scientific Literature
5.	ALA3068773	B	Inhibition of DUSP26 (unknown origin)-mediated p38 dephosphorylation	Homo sapiens	1	ALA3045606	single protein format	Scientific Literature
6.	ALA2363475	F	SANGER: Inhibition of human NCI-H1563 cell growth in a cell viability assay.	Homo sapiens	98	ALA1201861	cell-based format	Sanger Institute Genomics of Drug Sensitivity in Cancer
7.	ALA2363477	F	SANGER: Inhibition of human NCI-H1581 cell growth in a cell viability assay.	Homo sapiens	137	ALA1201861	cell-based format	Sanger Institute Genomics of Drug Sensitivity in Cancer
8.	ALA2363478	F	SANGER: Inhibition of human NCI-H1618 cell growth in a cell viability assay.	Homo sapiens	38	ALA1201861	cell-based format	Sanger Institute Genomics of Drug Sensitivity in Cancer
9.	ALA2363479	F	SANGER: Inhibition of human NCI-H1623 cell growth in a cell viability assay.	Homo sapiens	98	ALA1201861	cell-based format	Sanger Institute Genomics of Drug Sensitivity in Cancer
10.	ALA2363480	F	SANGER: Inhibition of human NCI-H1648 cell growth in a cell viability assay.	Homo sapiens	133	ALA1201861	cell-based format	Sanger Institute Genomics of Drug Sensitivity in Cancer
11.	ALA2363481	F	SANGER: Inhibition of human NCI-H1650 cell growth in a cell viability assay.	Homo sapiens	134	ALA1201861	cell-based format	Sanger Institute Genomics of Drug Sensitivity in Cancer
12.	ALA2363482	F	SANGER: Inhibition of human NCI-H1651 cell growth in a cell viability assay.	Homo sapiens	98	ALA1201861	cell-based format	Sanger Institute Genomics of Drug Sensitivity in Cancer
13.	ALA2363484	F	SANGER: Inhibition of human NCI-H1693 cell growth in a cell viability assay.	Homo sapiens	98	ALA1201861	cell-based format	Sanger Institute Genomics of Drug Sensitivity in Cancer
14.	ALA2363485	F	SANGER: Inhibition of human NCI-H1694 cell growth in a cell viability assay.	Homo sapiens	77	ALA1201861	cell-based format	Sanger Institute Genomics of Drug Sensitivity in Cancer
15.	ALA2363486	F	SANGER: Inhibition of human NCI-H1703 cell growth in a cell viability assay.	Homo sapiens	81	ALA1201861	cell-based format	Sanger Institute Genomics of Drug Sensitivity in Cancer
16.	ALA2363487	F	SANGER: Inhibition of human NCI-H1734 cell growth in a cell viability assay.	Homo sapiens	38	ALA1201861	cell-based format	Sanger Institute Genomics of Drug Sensitivity in Cancer
17.	ALA2363488	F	SANGER: Inhibition of human NCI-H1755 cell growth in a cell viability assay.	Homo sapiens	98	ALA1201861	cell-based format	Sanger Institute Genomics of Drug Sensitivity in Cancer
18.	ALA2363489	F	SANGER: Inhibition of human NCI-H1770 cell growth in a cell viability assay.	Homo sapiens	129	ALA1201861	cell-based format	Sanger Institute Genomics of Drug Sensitivity in Cancer
19.	ALA2363490	F	SANGER: Inhibition of human NCI-H1792 cell growth in a cell viability assay.	Homo sapiens	98	ALA1201861	cell-based format	Sanger Institute Genomics of Drug Sensitivity in Cancer
20.	ALA2363491	F	SANGER: Inhibition of human NCI-H1793 cell growth in a cell viability assay.	Homo sapiens	98	ALA1201861	cell-based format	Sanger Institute Genomics of Drug Sensitivity in Cancer